The imminent legalization of recreational marijuana in Canada has touched off a “boom” among up-and-coming producers.
And it has triggered a high-upside opportunity for investors looking to profit from Canada’s coming legalization this October.
While a number of licensed producers are now racing to meet expected demand, one company – an undervalued licensed producer that has seen rapid growth – could offer investors the most attractive way to play this unprecedented legalization opportunity.
That company is Maricann (CSE: MARI); (OTC: MRRCF) – a unique marijuana company that has seen rapid expansion and diversification…yet whose shares currently trade at a fraction of the valuations of other licensed producers in the space.
And with $180 million in capital raised to date – and over $34 million cash in the bank? after its recently completed financing of $37 million – the company is on sound financial footing and well-positioned for rapid growth.
The Rapid Rise of a $22.6 Billion Canadian Industry
According to industry expert Deloitte, the Canadian marijuana industry could rapidly grow in size to become a CAD $22.6 billion over the coming years.
This “once-in-a-lifetime” legalization opportunity has sparked a wave of expansion plans among licensed producers.
For those investors looking to take advantage of the surge in value enjoyed by many Canadian marijuana companies, there have been some impressive returns, including…
- Tilray, Inc. (TSE: TLRY) – up 202.94% over the past month and a half…
- Canopy Growth Corp. (TSE: WEED) – up 406.9% over the past 12 months.
- Aurora Cannabis (TSE: ACB) – up 180.7% over the past 12 months…
- The Hydrotherapy Corp. (TSE: HEXO) – up 210.1% over the past 12 months…
Those companies have seen large spikes in share price due in large part to their anticipated production capacity.
But as the October 2018 legalization of recreational marijuana in Canada rapidly approaches, under-the-radar Maricann (CSE: MARI); (OTC: MRRCF) remains undervalued by comparison…in spite of a number of distinct competitive advantages in both the medical and recreational sectors.
As legalization in Canada becomes a reality, production capacity and efficiency will become critical for licensed producers looking to thrive.
Maricann’s “Crown Jewel”:
A Low-Cost, High-Efficiency Facility
In the race to ramp up production for licensed producers, Maricann offers a critical “head start” of at least 3-4 years over other companies looking to enter the space, as licensing, planning and early construction have already been taken care of.
In Canada, Maricann’s (CSE: MARI); (OTC: MRRCF) Langton facility is the company’s crown jewel – a state-of-the-art facility with 217,000 square feet of grow and production space with annual capacity to grow up to 36,000 kilograms…which is worth an estimated $130 million in revenue.
This low-cost, high-efficiency facility includes a natural gas well and cogeneration facility on site, helping greatly reduce electricity costs. In addition, all water at the facility is recycled through a state-of-the-art biofilter helping ensure efficiency.
To date, the company has spent close to $50 million on building this facility, and its Phase 2 expansion – which would see it add an additional 635,000 square feet of grow space and bring its annual capacity up to 95,000 kilograms – is projected to be completed in 2019. This could potentially raise the annual revenue close to the $350 million mark based on Maricann’s (CSE: MARI); (OTC: MRRCF) current potential revenue of $180 million annually.
Automated Cultivation Facility Results in Greater Efficiency and Low-Cost Production
In addition, Maricann (CSE: MARI); (OTC: MRRCF) is the first company – via a partnership with Rockwell Automation – to create the world’s first fully-automated cultivation facility, resulting in ultra-high quality product.
In fact, only 26 employees are needed on the cultivation side of the business – as opposed to the 200-300 employees it takes to run a conventional grow operation in a similar-sized facility.
This allows Maricann (CSE: MARI); (OTC: MRRCF) to manage its production costs more effectively and with greater predictability, helping the company stake its claim as one of Canada’s lowest-cost, highest-quality producers.
Signed Distribution Agreements Are
Already in Place in Strategic Canadian Markets
These agreements mean that the company has “locked in” revenue of $50 million – and counting – from these strategic markets beginning in Canada.
This gives the company a tremendously valuable “head-start” in what figures to be a chaotic first few months of recreational legalization in Canada, as companies scramble to make agreements and ramp up production.
Tale of the Tape: Why Maricann is Canada’s Most Undervalued Licensed Producer
As investors begin to see the realities of Maricann’s (CSE: MARI); (OTC: MRRCF) production capacity – and its critical advantages over others in the industry – the company’s valuation could change in a meaningful way.
Take a look at this comparison chart showing the projected capacity of some of the industry’s more widely known producers for this fall and next summer…as well as the market cap for each of these companies.
Now take a look at the current market cap of Maricann (CSE: MARI); (OTC: MRRCF) and you can see that despite having a projected production capacity very much in line with the others on this list…the company would appear to be significantly undervalued for now.
The Advantage of Global Diversification
While the company appears poised to take advantage of the coming marijuana “boom” in Canada…it has also taken significant steps to position itself as a global leader ahead of legalization in other parts of the world.
Just recently – on August 15, 2018 – Maricann (CSE: MARI); (OTC: MRRCF) successfully exported its first shipment of dry cannabis flowers to Germany. The material – which was shipped from the Langton facility – met all specifications and requirements in Germany and the company will now move to export further product to the German medical marijuana market.
The German patient population is growing exponentially – up to over 16,000 patients from just 800 in 2016. Maricann (CSE: MARI); (OTC: MRRCF) is one of five companies with EU-GMP certified facilities for cannabis production globally, helping perfectly position Maricann to capture market share in the European medical market.
In addition, Maricann (CSE: MARI); (OTC: MRRCF) is working on a proposed 820,000 square-foot facility of cleanroom cultivation, processing and extraction on 164 hectares in Ebersbach, Germany, positioning itself to grow its European presence rapidly as cannabis legalization continues to sweep the European continent.
And in Switzerland, Maricann (CSE: MARI); (OTC: MRRCF) is currently producing out of a 60,000 square foot facility just outside of Zurich. Plans call for an upgrade of this facility and an increase in production by a factor of 6 in the near future.
Maricann is Backed by Some of the
World’s Largest Financial Institutions
While the company appears poised to take advantage of the coming marijuana “boom” in Canada.it has also taken significant steps to position itself as a global leader ahead of legalization in other parts of the world
Maricann (CSE: MARI); (OTC: MRRCF) is an ultra-low-cost cannabis producer and a leader in energy-efficient growth operations that has demonstrated its value and potential to a number of critical partners, institutional investors and investment banks.
And a number of large institutional investors – such as NewGen Funds, Polar, Industrial Alliance and Connor, Clark & Lunn – each hold sizable stakes.
Marijuana Companies Quickly Becoming Acquisition Targets of Beverage Giants
One of the more eye-opening trends in recent months has been the entry into the marijuana business – via acquisition and investment – by major alcoholic beverage companies.
These cannabis stock buyouts can potentially spark quick profits for early investors, as was the case with a major acquisition by Constellation Brands.
In October 2017, Constellation Brands – producer of Corona, Modelo and Pacifico beers, Mondavi wine and others – acquired a 10% stake in Canopy Growth Corp., a Canadian seller of medicinal marijuana products.
Then in August 2018, Constellation invested an additional $4 billion in Canopy Growth – taking the largest-known deal in the marijuana industry even further.
But Constellation is not the only large beverage company to get in on the potential for marijuana-infused beverages.
Molson Coors Canada recently teamed up with Canadian cannabis producer, The Hydropothecary (HEXO), to create a joint partnership “to pursue opportunities to develop non-alcoholic, cannabis-infused beverages for the Canadian market following legalization.”
“Canada is breaking new ground in the cannabis sector and, as one of the country’s leading beverage companies, Molson Coors Canada has a unique opportunity to participate in this exciting and rapidly expanding customer segment,” said Frederic Landtmeters, president and CEO of Molson Coors Canada.
And now the world’s fifth-largest alcoholic beverage company – U.K.-based Diageo – is reportedly interested in becoming the next large beverage firm to acquire a Canadian marijuana company.
Diageo is roughly twice the size of Constellation Brands with a market cap of $67.56 billion – and with annual sales of $12.1 billion – so its potential entry into the cannabis-infused beverage business would be another huge milestone for the rapidly-growing marijuana market.
A potential deal involving Diageo could be as large – if not larger – than Constellation Brands’ investment into the space, making it potentially the largest deal in the Cannabis Buyout Boom.
Yet Another Huge Advantage for Maricann
In the early stages of Canada’s marijuana “boom” the importance of experienced, capable leadership will be critical.
The potential associated with Maricann (CSE: MARI); (OTC: MRRCF) is clear: This is a licensed producer – with a global focused vision – well-positioned to take advantage of the coming “boom” in the Canadian cannabis market.
This is a licensed producer – with a global focused – well-positioned to take advantage of the coming “boom” in the Canadian cannabis market.
With a dynamic leadership team…critical partnerships all over the globe…significant technological advantages…and the backing of large institutional investors – there are a number of factors pointing in the favor of Maricann (CSE: MARI); (OTC: MRRCF).
But there is no greater consideration than the fact that – based on potential production capacity alone – Maricann appears to be significantly undervalued in comparison to its industry peers.
Those investors who are looking for the best way to take advantage of Canada’s coming cannabis growth should strongly consider the potential for Maricann (CSE: MARI); (OTC: MRRCF) to see a significant change in valuation in the months ahead.
ACB traded at $2.43 on 8/21/17 and at $6.82 on 8/20/18
HEXO traded at $1.49 on 9/11/17 and at $4.62 on 8/20/18
WEED traded at $8.84 on 8/21/17 and at $44.81 on 8/20/18
Disclaimer: This release/advertorial is a commercial advertisement prepared by Winning Media and is for general information purposes only. This is a Native Advertisement, meaning it is an informational paid marketing piece. Winning Media and the websiteMarijuanaStox.com make no recommendation that the securities of the companies profiled or discussed on this website should be purchased, sold or held by viewers that learn of the profiled companies through our website. Please review all investment decisions with a licensed investment advisor. This Advertorial was paid for by Maricann Group, Inc in an effort to enhance public awareness of Maricann Group, Inc and its securities. Winning Media has received a cash budget of one hundred thousand dollars by Maricann Group, Inc as a total production budget for this advertising effort. Neither Marijuanastox.com or Winning Media currently holds the securities of Maricann Group, Inc and does not currently intend to purchase such securities. This Advertorial contains forward-looking statements that involve risks and uncertainties. This Advertorial contains or incorporates by reference forward-looking statements, including certain information with respect to plans and strategies of the featured Company. As such, any statements contained herein or incorporated herein by reference that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words “believe(s)” “anticipate(s)”, “plan(s)” “expect(s)” “project(s)” “will” “make” “told” and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause actual events or actual results of the Company to differ materially from these indicated by such forward-looking statements. Certain statements contained herein constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934 and Canadian securities law. Further, this document includes statements regarding business, financing, business trends, future operating revenues and expenses and there can be no assurance that such expectations will prove to be correct. Investors are cautioned that any forward-looking statements made by the Company, or contained in this advertorial are not guarantees of future performance, and that the Issuer’s actual results may differ materially from those set forth in the forward-looking statements. Difference in results can be caused by various factors including, but not limited to, the Company’s ability to be able to successfully complete planned funding agreements, to successfully market its products in competitive industries or to effectively implement its business plan or strategies. To reiterate, information presented in this advertorial contains “forward-looking statements”. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact and may be “forward-looking statements.” Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this advertorial may be identified through the use of words such as “expects,” “will,” “anticipates,” “estimates,” “believes,” “may,” or by statements indicating certain actions “may,” “could,” or “might” occur. More information on the Company may be found at www.sec.gov readers can review all public filings by the Company at Maricann’s website and on SEDAR. Winning Media and MarijuanaStox.com are not certified financial analysts or licensed in the securities industry in any manner. The information in this Advertorial is subjective opinion and may not be complete, accurate or current and was paid for, so this could create a conflict of interest.